Cellular senescence, a form of cell cycle arrest, is a tumor suppressor mechanism triggered by multiple tumor promoting insults, including oncogenic stress and DNA damage. The role of cyclin-dependent kinase 2 (CDK2) regulation has been evaluated in models of replicative senescence, but little is known regarding its role in other senescence settings. Using in vitro and in vivo models of DNA-damage and oncogene-induced cellular senescence, it was determined that activation of the tumor suppressor protein p53 (TP53) resulted in repression of the CDK2 transcript which was dependent on intact RB.
Introduction:
Cellular senescence is a well-documented tumor suppressor response, which in most instances is dependent on functional TP53 (p53), and results in irreversible cell cycle exit, so preventing further tumor progression under the influence of oncogenic or genotoxic insults (reviewed in (1, 2)). Replicative senescence occurs due to telomere shortening, but senescence can also be induced by oncogene activation, loss of tumor suppressors, or direct DNA damage (reviewed in (3)). Cell cycle regulators are critically involved in the execution of the senescence response. In human fibroblasts, the cyclindependent kinase (CDK) inhibitors CDKN2a (p16 Ink4a ) and CDKN1A (p21 Cip1 ), are activated in response to oncogenic signals and are essential for cell cycle exit during cellular senescence (4) (5) (6) (7) (8) . In senescence caused by genotoxic insults, such as irradiation or topoisomerase inhibition, p53 is activated and this results in p21 Cip1 induction, which is essential for cell cycle exit and senescence (5, 9, 10) . In yet other in vivo settings, other CDK inhibitors, such as CDKN2B (p15 Ink4b ) and CDKN2C (p18
Ink4c
), have also been shown to play roles in this process (11, 12) .
In contrast to the well-documented roles of the CDK-inhibitors (p16 Ink4a , p21 Cip1 , p15
Ink4b
, p18
Ink4c
) in cellular senescence, the roles of the respective CDKs are not well defined.
The role of CDK2 has been primarily studied in the setting of replicative senescence, where several investigators have shown that activity of CDK2 decreases in senescent fibroblasts, likely through inhibition of Cyclin A/CDK2 complexes by p21 Cip1 , while CDK2 protein levels remain unchanged (13) (14) (15) ; whereas in replicative senescence of cultured human umbilical vein endothelial cells, reduction of both CDK2 activity and protein levels were noted (16) . Transduction of replicatively senescent cells with Cyclin E/CDK2 complexes results in cell cycle re-entry in a subset of cells, indicating that reduction of CDK2 activity is indeed essential for replicative senescence (17) .
In oncogene-induced senescence, limited data is available, but suggests a physiologic role for CDK2 in opposing senescence. For instance, in RAS V12 -induced senescence, endogenous CDK2 activity is reported to be decreased (6) . MYC-induced senescence occurs in a Cdk2-null background (and upon pharmacologic CDK2 inhibition in fibroblasts), but not in Cdk4-null or Cdk6-null backgrounds (18) . We previously showed that in a mouse model of CCND1 (Cyclin D1)-driven senescence, CDK2 protein levels are also markedly decreased (19) . All the above data together prompted us to investigate the role of CDK2 in oncogene-induced and DNA damage-induced senescence. In this report, we uncover a central physiologic role for p53-mediated repression of CDK2 during oncogene-induced senescence, and highlight CDK2 as a possible target to limit premalignant lesions, as well as inhibit progression of established cancer, via induction of senescence.
Materials and Methods: Mouse Studies
Irbp-Cyclin D1 transgenic mice (20) were bred with p53 -/-mice (Jackson Laboratory, Maine) or p53ERTAM ki/ki mice (21) and maintained in a mixed C57BL/6 × 129/Sv genetic background. PCR for targeted alleles was used to verify mouse genotypes as described (20) (21) (22) . Animals were euthanized at defined time points or when obviously ill in accordance with the American University of Beirut Institutional Animal Care and Use Committee guidelines; all animal studies were approved by this committee.
For all in vivo studies, CVT313 was administered by once daily intraperitoneal injection of 1.25 mg/kg. For BrdU incorporation assays, mice were given an intraperitoneal injection of 50 mg/Kg of BrdU (Sigma-Aldrich, St Louis, MO), every 2 hours × 5 and sacrificed 2 hours later.
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Human BJ foreskin fibroblasts (ATCC) were cultured at 37°C and 5% CO 2 For Rb fl/fl MEFs, Rb knock out was perfomed by using Cre-mediated recombination via lentiviral transduction. Successful recombination was assessed by PCR and western blot.
For senescence induction, cells were exposed to 20 Gy irradiation at 1 Gy/min, or treated with 10 ȝM Etoposide. Cells were treated with CVT313 at 5 ȝM (Santa Cruz Biotechnology, Santa Cruz, CA) for CDK2 inhibition, with NSC625987 at 1 ȝM (SigmaAldrich) for CDK4 inhibition, with Flavopiridol at 1 ȝM (Sigma-Aldrich) for total CDKs inhibition or corresponding volume of DMSO vehicle; media was renewed every 3 days.
For viral transductions, cells were plated in 6-well plates at a density of 200,000 cells per well. Virus was added to the cells with 8 ȝg/ml Polybrene (hexadimethrine bromide, Sigma). Spinoculation was performed at 32 o C, 2500 rpm for 2 hours and medium was replaced after 3 hours. The following day, the procedure was repeated. For SABG staining, cells were fixed and stained overnight at 37°C, and counterstained with eosin, as in our previous studies (12, 19) . For BrdU incorporation assays, cells were treated with
BrdU at a concentration of 33 ȝM for 2 hours, fixed with 50% methanol / 50% acetone 9 9
dispersed, and cells were plated onto 8-well permanox chamber slides (Nunc, Rochester, NY), and cultured in DMEM with 10% FBS, 1% glutamine, and 1% Pen/Strep.
Explanted cells were treated with CVT313 (Santa Cruz Biotechnology) or DMSO vehicle; media was renewed every 3 days, and cells were fixed after 7 days. BrdU and SABG staining and cell counting were performed as detailed above. Digital photomicrographs were analyzed using Adobe Photoshop CS4 software.
Histological studies and Immunostaining
Brain tissue was fixed in 4% paraformaldehyde for 72 hours then embedded in paraffin. 
Analysis of protein expression
Protein lysates were prepared from cultured cells or pineal tissue in Universal Lysis Buffer, as previously described (19) . Electrophoresis was performed using 12% TrisChloride gels, and proteins were transferred to polyvinylidene difluoride membranes (Bio-Rad Laboratories, Hercules, CA), and detected using antibodies to p21
Cip1 , p15 
RNA extraction and Quantitative real-time PCR:
Total RNA was extracted using Trizol reagent (Invitrogen) according to the manufacturer's instructions. DNAse-treated total RNA was used for cDNA synthesis with random hexamers using RevertAid 1st strand cDNA synthesis kit (Fermentas). Real-time PCR was performed using the iQ SYBR Green Supermix in a CFX96 system (Bio-Rad Laboratories). Products were amplified using the following primers: GAPDH, forward = AGCCAAAAGGGTCATCATCT; reverse = GGGGCCATCCACAGTCTTCT; mature Cdk2, and 55°C for preprocessed Cdk2 transcript. A final extension at 72°C for 10 min was performed followed by a melting curve, with temperature gradually increased (0.5°C) to 95°C. Standard curves were plotted using serially diluted cDNA. The geometric mean of housekeeping gene GAPDH was used as an internal normalization control.
Statistical Analysis:
Comparisons between experimental groups were performed using Student's t-test, and a p-value below 0.05 was considered as statistically significant. Survival curves were generated as per the method of Kaplan and Meier. 
Results:
CDK2 protein levels are decreased during both oncogene-induced and DNA damageinduced senescence: We had previously noted that CDK2 protein levels decrease in an in vivo model of cellular senescence, wherein exogenous expression of Cyclin D1 in pineal cells leads to a pre-tumorigenic hyperplastic lesion limited by p53-dependent senescence (19) . To verify whether down-regulation of CDK2 holds true in other instances of senescence induction, we used two well-documented in vitro models of senescence -
Ras
V12 -induced senescence and DNA damage-induced senescence, using MEFs and human BJ fibroblasts. Senescent cells in both of these well-established and previously studied systems displayed cell cycle exit (evidenced by absence of BrdU incorporation into DNA) and positive staining for senescence-associated beta-galactosidase (SABG)
[ Figure 1A ], in addition to other markers of senescence such as expression of p21 Cip1 , p15 Ink4b , p16 Ink4a , and DcR2 [ Figure 1B ]. Interestingly, CDK2 protein levels were specifically decreased in senescent cells whereas the levels of another S-phase kinase CDK1, and the G1/S kinase CDK4, were unchanged [ Figure 1C and 1D]. Concomitant with the decrease in CDK2 levels, we found decreased levels of its target phosphoHistone 1 [ Figure 1C ], and decreased phosphorylation of the retinoblastoma protein RB1
(RB) at Ser612, a CDK2-specific phosphorylation site (25) [ Figure 1C ]. FACS analysis showed that senescent cells were arrested in G0/G1, as expected (data not shown). Timed analysis showed that the decrease in CDK2 protein levels occurred at around 5 days after the insult [ Figure 1D ], which correlated temporally with the timing of cell cycle exit and preceded SABG positivity [ Figures 1E and 1F ].
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CDK2 repression during senescence occurs at an mRNA level, in a p53-dependent and RB-dependent manner: This temporal lag of 5 days between oncogenic or DNA damageinducing insult and CDK2 down-regulation [see Figure 1D ] suggested the possibility of transcriptional repression of CDK2 during senescence induction. To investigate this, we evaluated the expression levels of mature and primary Cdk2 mRNA transcripts during senescence both in vitro and in vivo. We found the levels of mature Cdk2 mRNA to be significantly decreased at senescence in vitro in p53-wild type MEFs [ Figure 2A ], but not in p53-null MEFs that were exposed to the same insults but failed to undergo senescence [ Figure 2B ]. Similarly, in the Irbp-Cyclin D1 mouse, a well-characterized in vivo model of p53-dependent Cyclin D1-induced senescence that limits development of the brain tumor pineoblastoma (12, 19) , tissue from senescent pineal hyperplastic lesions driven by Cyclin D1 (PG-S) exhibited marked down-regulation of mature Cdk2 mRNA compared with pre-senescent hyperplastic lesions (PG-PS) [ Figure 2C ]. We next evaluated the expression of the primary (pre-processed) Cdk2 mRNA transcript and found that levels of expression were also significantly decreased during senescence in p53-wild type MEFs [ Figure 2D ], but not in non-senescent p53-null MEFs [ Figure 2E ]. Similarly, primary mRNA transcript expression levels were decreased in senescent pineal cells in vivo
The lack of repression of CDK2 in p53-null cells and tissues [see Figures 2B and 2E] suggested that CDK2 down-regulation is a downstream consequence of p53 activation.
To test this, we used MEFs derived from the reversibly regulatable p53ER(TAM) KI CDK2 has been shown to be a transcriptional repression target of the RB/E2F complex (26, 27) . In addition, a well recognized mechanism of p53-induced cell cycle exit is via induction of p21 Cip1 , which then results in inhibition of S-phase Cyclin /CDK complexes, leading to dephosphorylation and activation of RB (28, 29) . To formally assess whether We therefore conclude from the above results that CDK2 downregulation during oncogene-induced senescence occurs at the mRNA level, via a p53-dependent and RBmediated mechanism. We hypothesize that the most likely mechanism is through p53-mediated p21
Cip1 induction (which occurs during senescence as seen in Figure 1B ), leading to RB activation and subsequent repression of CDK2 transcription (26, 27) .
However, this still needs to be formally proven in future studies. 
senescence (12, 19) . Treatment of young mice (at post-natal day (P)10) with CVT313 resulted in effective CDK2 inhibition in Irbp-Cyclin D1 mice of both wild-type and p53-null background, as shown by decreased phosphorylation of the CDK2 target Histone 1 in harvested pineal tissue [ Figure 6A ]. While the pineal cells of control, untreated mice show no senescence phenotype until around 7 weeks of age (postnatal day (P)49) (12, 19) , inhibition of CDK2 for as few as 10 days (P10-P20) resulted in a dramatically advanced onset of senescence, evident as loss of Ki67 positivity and development of senescence-associated heterochromatin foci (SAHF) that start to become visible as early as 6 days after treatment with CDK2 inhibitor (P16), and become readily apparent by 10 days after treatment (P20) [ Figure 6B ].
We next evaluated the effect of CDK2 inhibition in p53-deficient Irbp-Cyclin D1 mice.
In such animals, proliferation in the transgenic pineal gland continues unabated without senescence induction due to absence of p53 and invasive pineal tumors develop uniformly by 3 months of age (12) . Treatment of these Irbp-Cyclin D1, p53-/-mice with CVT313 between P10 and P20 resulted in mixed phenotypes, some mice showing enhanced pineal cell senescence, while others appeared unaffected by CVT313 [ Figure   6C , left panel: (1) and (2) Figure 6D ]. Conversely, pineal glands in which CVT313 treatment had no detectable inhibitory effect on proliferation showed high levels of phosphorylation of the CDK2 targets pH1 and pRB-Ser612 [ Figures 6C and 6D] . Importantly, in both cases, the cells that acquired SAHF were distinct from cells that continued to proliferate, shown by distinct staining for H3K9me3 and BrdU in dual stained sections [ Figure 6E ].
To evaluate any impact of CDK2 repression on tumor onset, we treated a cohort of IrbpCyclin D1, p53-/-mice (n=8) with CVT313 for ten days (P10 through P20, as above) and monitored their survival. While untreated mice developed clinically apparent pineal tumor at a median age of 85 days, the treated mice exhibited significant delay in tumor onset, with a median prolongation of tumor-free survival of more than one month [ Figure   6F , p < 0.001].
Discussion:
Our current study now identifies p53-dependent and RB-mediated down-regulation of Cdk2 as an essential physiological tumor suppressive mechanism, triggered by both oncogene-induced and DNA-damage-induced senescence. Much insight has been gained over the past decade into mechanisms underlying induction of cellular senescence in tumor suppression, including the central role of the p53 pathway, typically activated by DNA damage response signals, and the importance of the RB pathway, which contributes to formation of SAHF (reviewed in (1, 2, 31) ). During the onset of senescence, the
CDK2-inhibitor p21
Cip1 is up-regulated together with the CDK4/6-inhibitor p16 Ink4a , both of which contribute to cell cycle exit, as are the CDK4/6 inhibitors p15 Ink4b and p18 in a manner dependent upon MYC phosphorylation by CDK2 (35) . These studies show that CDK2 activity is critical for circumventing senescence during MYC-induced transformation. Our work now establishes an essential role for physiologic CDK2 downregulation during p53-mediated senescence induced by DNA damage or oncogenic insult.
As mentioned above, previous work has established that CDK2 kinase activity (but not CDK2 protein levels) is decreased during replicative senescence (13) (14) (15) 36 specific regulation of CDK2 in this setting. Our study now shows that, in both oncogeneinduced and DDR-induced cellular senescence, the cell cycle exit that underpins senescence induction requires p53-dependent down-regulation of CDK2. In our studies, expression of exogenous CDK2 prior to senescence resulted in complete bypass of senescence, evidenced by continued DNA synthesis and restoration of proliferative capacity in the face of oncogenic or DNA damage stress. However, in our system, the levels of exogenously expressed CDK2 were much higher than those seen in parental cells, and therefore we cannot exclude the possibility that some of the effects seen may be related to non-physiologic effects due to over-expression of the protein. Notably, levels of CDK2 protein were similarly high in RB-deficient cells (likely due to loss of the feedback inhibitory loop via RB/E2F-mediated transcriptional repression), and these RBdeficient cells also do not undergo senescence. A possible role for the level of protein expression of CDK2, if any, would need to be further evaluated using more refined tools that would allow titration of CDK2 protein expression level, in both RB-deficient and RB-wild type cells. Interestingly, we found that expression of CDK2 after onset of senescence failed to reverse the phenotype, suggesting that CDK2 repression is needed to execute the cell cycle exit accompanying senescence, but is not needed for maintenance of senescence once established.
Our work further shows that the p53-dependent downregulation of CDK2 is also dependent on intact RB, suggesting that RB activation is upstream of CDK2, likely through E2F-mediated transcriptional repression, as CDK2 is a well described target of active RB/E2F complexes (26, 27) Cip1 (induced by p53), as well as by INK4 proteins, both of which are induced during senescence in the above described models, as previously shown (see Figure 1B and references (12, 31, 37) ) .
While the most well studied phosphorylation target of CDK2 is the RB protein, CDK2
acts to phosphorylate multiple other proteins important in cell cycle regulation.
CDK2 becomes activated in late G1 phase of the cell cycle, upon complexing with Cyclin E. The Cyclin E-CDK2 complex then acts to phosphorylate multiple substrates, including the retinoblastoma protein (pRB), Histone 1, p27 Kip1 , and MYC (reviewed in (34, 38) ).
Hyper Of note, while the senescence phenotype in p53-deficient animals was quite variable, it seemed to correlate with the variability in the extent of inhibition of CDK2 activity. As such, persistent phosphorylation of the CDK2 substrates Histone 1 and RB (at Ser 612) correlated with continued proliferation and lack of formation of SAHF, suggesting that complete inhibition of CDK2 activity is needed for induction of the senescent phenotype.
While in p53-proficient mice, CDK2 activity was completely abolished by the used doses of CVT313, this was obviously not the case in p53-deficient mice, and varied among animals. Possibly, this reflects variable degrees of complementation by other CDKs - 
perhaps CDK1, which is known to be capable of phosphorylating CDK2 targets (39) and may be expressed at increased levels in cells lacking p53 (40) .
Why CDK2 inhibition elicits features of senescence in Irbp-Cyclin D1, p53-/-pineal cells both in vivo and in vitro when it fails to do so in HRas V12 -transduced p53-/-MEFs in vitro, remains unclear but may be due to intrinsic cell type-specific differences, as well as oncogene-specific responses. Indeed, similar differences have been observed in other studies; for example, Campaner et al. found that lymphomas arising in Eȝ-myc mice are delayed when mice are crossed into a Cdk2-/-genotype background; however, in the absence of p53, this delay is abolished, indicating that it is p53-dependent. On the other hand, when they tested a panel of MYC-expressing cell lines, they found that CDK2 inhibition facilitated MYC-induced senescence even in the absence of p53 (18) . In another study, transfection of SAOS osteosarcoma tumor cells with dnCdk2 induced senescence, even in the absence of pRb and p53 (41) . These data, in addition to our current work, suggest that the response of different cell types to CDK2 inhibition, and the relationship of that response to the specific oncogenic insult, needs to be further investigated so as to optimize CDK2 as a target in cancer therapy.
Our study identifies p53-dependent repression of CDK2 as a key mechanism during cellular senescence, essential for cell cycle exit. It also suggests that, clinically, CDK2 
data also support the notion that CDK2 inhibition will be therapeutically useful in inducing senescence and preventing further proliferation even in lesions that have already lost p53; however, in such cases, and as can be deduced from findings of our in vivo studies, it will be essential to achieve complete inhibition of CDK2 activity, together with any potential redundant CDK activities, in order to achieve effective cell cycle exit and inhibition of tumor progression. 
